

What is claimed is:

1. A composition for initiating an immune response against an immunodeficiency virus comprising an antigen-presenting cell pulsed with an inactivated virus.
2. The composition of Claim 1, wherein the composition initiates an immune response against a Human Immunodeficiency Virus (HIV).
3. The composition of Claim 1, wherein the composition initiates an immune response against a Simian Immunodeficiency Virus (SIV).
4. The composition of Claim 1, wherein the antigen presenting cell is a monocyte-derived dendritic cell.
5. The composition of Claim 4, wherein the monocyte-derived dendritic cell is immature.
6. The composition of Claim 1 further comprising a protease inhibitor.
7. The composition of Claim 6, wherein the protease inhibitor is an Human Immunodeficiency Virus (HIV) protease inhibitor.
8. The composition of Claim 7, wherein said HIV protease inhibitor is indinavir.
9. The composition of Claim 6, wherein said HIV protease inhibitor is present in the composition at non-antiviral doses.
10. The composition of Claim 6, wherein said HIV protease inhibitor is present in the composition at antiviral doses.
11. The composition of Claim 1, wherein said inactivated-virus is an inactivated autologous virus.
12. The composition of Claim 11, wherein said inactivated-autologous-virus is an inactivated autologous human immunodeficiency virus (HIV).

13. The composition of Claim 11, wherein said inactivated-autologous-virus is an inactivated autologous simian immunodeficiency virus (SIV).
14. A composition for expanding expression of virus-specific CB8+T cells, comprising an autologous dendritic cell pulsed with an inactivated human immunodeficiency virus (HIV).
15. The composition of Claim 14, wherein said virus-specific CB8+T cells kill HIV-infected cells.
16. The composition of Claim 14, wherein said virus-specific CB8+T cells suppress HIV Type 1 (HIV-1) replication.
17. The composition of Claim 14, wherein said virus-specific CB8+T cells substantially eradicate HIV-1 in peripheral blood mononuclear cells (PBMC).
18. The composition of Claim 14, which increases HIV-specific cytotoxic-T-lymphocyte (CTLE) activity of autologous peripheral blood lymphocytes.
19. A method of eradicating HIV infected cells in a mammal comprising:
 - culturing T cells from the mammal;
 - expanding said T cells with an inactivated-virus-pulsed autologous dendritic cell;and
 - exposing said cells harboring HIV to the T cells expanded with the inactivated-virus-pulsed autologous dendritic cell.
20. A composition for initiating an immune response against human immunodeficiency virus (HIV) comprising an inactivated human immunodeficiency virus (HIV)-pulsed dendritic cell, wherein said inactivated-HIV-pulsed dendritic cell expands expression of virus-specific CD8+T cells which kill HIV-infected cells.

21. A method of controlling an immunodeficiency viral load of a mammal, comprising the steps of administering the composition of Claim 1 at a dosage and for a time sufficient to reduce the immunodeficiency viral load.
22. A method of inducing an immune response in a mammal, comprising administering the composition according to Claim 1 to said mammal at a dosage and for a time sufficient to induce protective immunity against subsequent infection.
23. A method of inducing production of antibodies to HIV in a human, comprising administering to the human a substantially purified dendritic cell pulsed with an inactivated HIV.
24. A method of inducing production of antibodies to SIV in a monkey, comprising administering to the monkey substantially purified and inactivated SIV-pulsed dendritic cells.
25. An anti-HIV vaccine comprising autologous inactivated whole HIV-pulsed dendritic cells.
26. A method of inducing an anti-HIV immune response in a mammal, comprising administering the vaccine of Claim 25 to said mammal in a therapeutically effective dosage effective to elicit an immune response to protect said mammal against subsequent infection with at least one strain of HIV.
27. A method of inducing production of anti-HIV immunity in a mammal comprising administering to the mammal:
 - a substantially purified autologous HIV-virus; and/or
 - an autologous host cell infected with the inactivated autologous HIV-virus; and
 - an autologous host cell infected with an autologous attenuated HIV-virus.

28. The method of Claim 27, further comprising recovering and purifying said anti-HIV antibodies.
29. A method of treating a mammal for HIV infection, comprising administering an antibody obtained by the method of Claim 27 to said mammal in a therapeutically effective dosage to reduce one or more symptoms associated with said HIV infection.
30. A composition for expanding the expression of virus-specific CD8+T cells which kill HIV-infected cells and suppressing HIV type 1 (HIV-1) replication, comprising an inactivated virus pulsed dendritic cell and an HIV protease inhibitor.
31. A method of inducing production of anti-HIV immunity in a mammal comprising administering to the mammal an autologous dendritic cell pulsed with the inactivated autologous HIV-virus.
32. The method of Claim 31, further comprising the step of administering an HIV protease inhibitor.